Apichot So-NgernBuddharat Khan-AsaPreecha MontakantikulWeerawat ManosuthiSiam UniversityThailand Ministry of Public HealthMahidol UniversityFaculty of Medicine, Siriraj Hospital, Mahidol University2019-08-282019-08-282018-01-01Southeast Asian Journal of Tropical Medicine and Public Health. Vol.49, No.1 (2018), 60-67012515622-s2.0-85054815476https://repository.li.mahidol.ac.th/handle/20.500.14594/47175© 2018, SEAMEO TROPMED Network. All rights reserved. The objective of this study was to determine the prevalence of dyslipidemia, pattern of lipid profiles, and risk factors for dyslipidemia. This study was a retrospective cross sectional study of the outpatient Thai HIV-infected patients receiving antiretroviral therapy (ART). Of 175 patients, 43% were male and median (IQR) age was 44 (40-51) years. Median (IQR) duration of HIV infection was 15 (13-16) years and median (IQR) duration of receiving ART was 11 (9-14) years. The prevalence of dyslipidemia was 51%. Dyslipidemia were associated with 76%, 55%, and 37% of patients receiving lopinavir/ritonavir-, efavirenz-, and nevirapine-based regimen, respectively. Medians serum low-density lipoprotein cholesterol (LDL-c) level for the corresponding regimens were 112, 136, and 107 mg/dl, respectively. The medians of serum triglycerides (TG) for the corresponding regimens were 162, 138, and 100 mg/dl, respectively. By multivariate analysis, risk factors associated with dyslipidemia included fasting blood glucose >110 mg/dl (OR=9.48), lopinavir/ritonavir-based regimen (OR=4.26), duration of receiving ART ≥12 years (OR= 2.69), and male (OR=2.29). Dyslipidemia associated ART was a common metabolic complication among even Thai HIV-infected patients, receiving ART in the outpatient clinic, especially patients received lopinavir/ ritonavir-based regimen. Thus, clinicians should monitor these metabolic complications to improve quality of care.Mahidol UniversityMedicineArticleSCOPUS